This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


* The AMPLIFY-EXT clinical trial was a 12-month, randomised, double-blind placebo-controlled trial in 2,482 patients with VTE who had been treated for 6–12 months with standard anticoagulation therapy or had completed treatment with ELIQUIS or enoxaparin / warfarin as participants in the AMPLIFY trial and for whom there was clinical uncertainty about the benefit of continuing treatment.1

The primary efficacy endpoint was the composite of symptomatic recurrent VTE or death from any cause.1 Recurrent VTE included fatal or non-fatal PE and DVT.1

The primary safety endpoint was major bleeding.1 For patients who had more than one event, only the first was counted.1

§ The secondary safety endpoint was the incidence of major or CRNM bleeding events.1 For patients who had more than one event, only the first was counted.1

This link is to a third-party site unaffiliated with the BMS / Pfizer Alliance. Please abide by the terms of use of the site.

ARR = Absolute Risk Reduction   BD = Twice Daily   CI = Confidence Interval   
DVT = Deep Vein Thrombosis   N = Total number of patients in either the ELIQUIS group or the placebo group   n = Number of patients with event   PE = Pulmonary Embolism   RR = Relative Risk   
SmPC = Summary of Product Characteristics   
VTE = Venous Thromboembolism


  1. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at